A scientific journal has retracted a landmark study on the safety of Monsanto's Roundup herbicide, citing 'serious ethical concerns' and casting doubt on the integrity of the research. This decision has sparked a firestorm of controversy, especially given the study's significant role in Monsanto's defense against cancer-related claims.
The study, published in 2000, was a sweeping evaluation of the safety of Roundup and its active ingredient, glyphosate. It concluded that these weed killers posed no health risks to humans, including no cancer risks, reproductive issues, or adverse effects on endocrine systems. This conclusion has been a cornerstone of Monsanto's defense in numerous lawsuits alleging that Roundup causes cancer.
But here's where it gets controversial: the study's authors were not Monsanto employees. The listed authors were three scientists, Gary Williams, Robert Kroes, and Ian Munro, who were seemingly independent researchers. This gave the study added credibility and was used by Monsanto to counter conflicting scientific evidence linking Roundup to cancer.
However, internal company documents revealed in litigation tell a different story. Monsanto's influence on the study was substantial. Emails show that Monsanto employees were heavily involved in the research and celebrated its publication as a strategic victory. The company even planned to use the study to differentiate itself from generic competitors.
One Monsanto scientist, William Heydens, suggested in an email that they 'ghost-write' another paper, paying outside scientists to put their names on work done by Monsanto employees. This strategy was apparently used for the Williams, Kroes, and Munro study, as Monsanto employees were praised for their 'hard work' on the 'independent' research.
The retraction of this study is a significant development, as it calls into question the validity of Monsanto's defense in ongoing lawsuits. It also highlights the potential for corporate influence on scientific research. Brent Wisner, a lawyer involved in the litigation, called it a 'quintessential example of how companies like Monsanto could undermine the peer-review process.'
The timing of the retraction is notable, as it coincides with the Trump administration's support for Bayer's (Monsanto's parent company) bid to curtail thousands of lawsuits. The EPA, while not relying on the retracted study, has stated that glyphosate can be used safely and is not carcinogenic, based on their own assessments.
This story raises important questions about the integrity of scientific research and the influence of corporate interests. Are we seeing a case of corporate manipulation of science, or is this a one-off incident? What does this mean for the ongoing legal battles and the future of scientific publishing? The debate is sure to continue, and the public's right to know and understand the truth is at the heart of it all.
